Don't Buy Bionano Genomics (BNGO) Before Checking Its Fundamentals!

Bionano Genomics moved -2.6% this afternoon session, trading between a high of $0.6991 and a low of $0.6231 per share. Yesterday the stock finished at $0.67 per share, compared to an average analyst target price of $4.06.

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The small-cap biotechnology: laboratory analytical instruments company is based in the United States, and over the last twelve months it has returned a dividend yield of None%. Bionano Genomics has trailing twelve months earnings per share (EPS) of -0.48, which at today's prices amounts to a price to earnings (P/E) ratio of -1.4.

Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of None. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.

Overview of the Company's Gross Margins:

Date Reported Revenue ($ k) Cost of Revenue ($ k) Gross Margins (%) YoY Growth (%)
2022-12-31 27,802 21,857 21.38 -0.74
2021-12-31 17,981 14,107 21.54 -33.95
2020-12-31 8,503 5,730 32.61 -1.72
2019-12-31 10,130 6,768 33.18 n/a

Bionano Genomics's 27.2% average gross margins are thinner than the 57.74% average of the Biotechnology industry, implying that the firm might be lacking in competitivity.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.